- Home
- GLV vs IMA Comparison
GLV vs IMA Comparison
Compare GLV & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$6.50
Company Overview
Basic Information| Metric | GLV | IMA |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 65.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLV | IMA |
|---|---|---|
| Price | $5.99 | $6.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 54.2K | ★ 63.4K |
| Earning Date | 01-01-0001 | 02-15-2026 |
| Dividend Yield | ★ 12.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $5.75 |
| 52 Week High | $6.06 | $18.00 |
Technical Indicators
Market Signals| Indicator | GLV | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | N/A |
| Support Level | $5.85 | N/A |
| Resistance Level | $6.02 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 48.00 | 0.00 |
Price Performance
Historical Comparison GLV
IMA
About GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.